This finding suggests that RPL41 may have an indirect effect on antigen presentation—research related to prostate cancer also supports this hypothesis, demonstrating that the silencing of ARL5B is associated with an increased expression of MHC class I molecules on the surface of tumor cells (51). Here, ARL5B is linked to prostate carcinoma.